Shares of Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) have been assigned a consensus rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $6.33.
A number of analysts have weighed in on ARPO shares. Zacks Investment Research downgraded shares of Aerpio Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Wednesday, June 5th. HC Wainwright reissued a “hold” rating on shares of Aerpio Pharmaceuticals in a report on Friday, April 5th. Cantor Fitzgerald set a $8.00 price target on shares of Aerpio Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 5th. Guggenheim downgraded shares of Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, March 18th. Finally, National Securities downgraded shares of Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, March 18th.
In other news, major shareholder Bioventures Ltd Novartis sold 231,763 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $0.94, for a total transaction of $217,857.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 1,750,446 shares of company stock valued at $1,774,045 over the last ninety days. 38.60% of the stock is owned by insiders.
Shares of Aerpio Pharmaceuticals stock opened at $0.88 on Wednesday. Aerpio Pharmaceuticals has a fifty-two week low of $0.86 and a fifty-two week high of $4.35. The firm has a fifty day moving average of $1.01.
Aerpio Pharmaceuticals (OTCMKTS:ARPO) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.